LH
Labcorp Holdings Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Labcorp Holdings Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
No other changes.
No other changes.
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Annual filing, covered
10-K parsed · Feb 24 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 24 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
+8.78%
vs ±5.7% implied · ×1.55
shaded = implied · ▲▼ = realized
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $1.8B | 8.33% | +2.01% |
| Vanguardindex-like | $1.5B | 6.79% | −0.26% |
| Victory | $1.4B | 6.13% | +4.55% |
| State Streetindex-like | $1.1B | 4.95% | +1.15% |
| Vanguard Portfolioindex-like | $1.0B | 4.66% | −0.05% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $1.8B | 8.33% | +2.01% |
| Vanguardindex-like | $1.5B | 6.79% | −0.26% |
| Victory | $1.4B | 6.13% | +4.55% |
| State Streetindex-like | $1.1B | 4.95% | +1.15% |
| Vanguard Portfolioindex-like | $1.0B | 4.66% | −0.05% |
Labcorp Holdings Inc.
352.83
−2.76 · −0.78%
post 352.83 0.00%
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Veracyte, Inc., RadNet, Inc. and 3 more; of Labcorp Holdings Inc.'s 6 closest co-movers, 1 shares that code.
Same SIC code · 6
Same SEC industry code: Quest Diagnostics Inc, Veracyte, Inc., RadNet, Inc. and 3 more; of Labcorp Holdings Inc.'s 6 closest co-movers, 1 shares that code.
Tall tick = annual report · Source: EDGAR
Linked news
Bull4
Bear1
Expected move
Inputsspot 356.80exp Feb 19ATM strike 360ATM straddle 37.80IV 25%